[Central venous catheter and malignant disease. The value of thrombosis prophylaxis is questioned now].
Jansson
Jan-Håkan
JH
Institutionen för folkhälsa och klinisk medicin, Umeå universitet. janhakan.jansson.ss@vll.se
D000925:Anticoagulants / Q000008:administration & dosage; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D017410:Practice Guidelines as Topic; D020246:Venous Thrombosis / Q000209:etiology* / Q000517:prevention & control; D014859:Warfarin / Q000008:administration & dosage
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin